NCT03905447 is a Phase 2 clinical trial of PC945 in Aspergillosis, sponsored by Pulmocide Ltd.

Who is sponsoring NCT03905447?

NCT03905447 is sponsored by Pulmocide Ltd.

What drugs are being tested in NCT03905447?

Interventions in NCT03905447: PC945, Standard of Care.

What condition does NCT03905447 study?

NCT03905447 studies Aspergillosis, Lung Transplant Infection.

Is NCT03905447 still recruiting?

NCT03905447 is currently terminated. Last updated 16 July 2021.

Last reviewed 2021-07-16 · How we verify

NCT03905447

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effect of Early Treatment of PC945 on Aspergillus Fumigatus Lung Infection in Lung Transplant Patients.

Terminated Phase 2 Last updated 16 July 2021

What this trial tests

Phase 2 trial testing PC945 in Aspergillosis in 2 participants. Terminated before completion.

Timeline

17 September 2019

Primary endpoint
1 June 2020

1 June 2020

Quick facts

Lead sponsor	Pulmocide Ltd
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	2
Start date	17 September 2019
Primary completion	1 June 2020
Estimated completion	1 June 2020
Sites	3 locations across United Kingdom

Drugs / interventions tested

PC945 — full drug profile →
Standard of Care

Conditions studied

Aspergillosis — all drugs for Aspergillosis →
Lung Transplant Infection — all drugs for Lung Transplant Infection →

Sponsor

Pulmocide Ltd — full company profile →

Who can join

Adults 18 to 85, any sex, with Aspergillosis or Lung Transplant Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study tests the effects of pre-emptive treatment with an experimental drug PC945 in lung transplant recipients whose lungs are infected by the fungus Aspergillus fumigatus. PC945 may be useful in treating patients infected with Aspergillus fumigatus as, unlike the usual treatments, it is inhaled into the lung and has been designed to stay there and treat the infection. Participants will be monitored for up-to 12 weeks for the presence of Aspergillus in their lungs. Suitable participants will receive PC945 for an initial 28 days (Pre-emptive treatment phase) and, if needed, a further 8-weeks (Extended treatment phase).The amount of fungus in the patients' lungs will be measured over the course of the study. Participants with lung infections but not eligible for PC945 will be followed-up for 16-weeks on standard of care treatment. The study will take place at multiple sites in UK and 10 participants will receive PC945. The maximum study duration will be about 28 weeks.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

New Antifungal Agents with Azole Moieties.
Teixeira MM, Carvalho DT, Sousa E, Pinto E. · · 2022 · cited 44× · PMID 36422557 · DOI 10.3390/ph15111427
Promising Drug Candidates and New Strategies for Fighting against the Emerging Superbug <i>Candida auris</i>.
Billamboz M, Fatima Z, Hameed S, Jawhara S. · · 2021 · cited 39× · PMID 33803604 · DOI 10.3390/microorganisms9030634

Verify or expand the search:

Other trials of PC945

Trials testing the same drug.

NCT05238116 — Safety and Efficacy of PC945 (Opelconazole) in Combination With Other Antifungal Therapy for the Treatment of Refractory · Phase 3 · terminated
NCT03870841 — The Effect of PC945 on Aspergillus Fumigatus Lung Infection in Patients With Cystic Fibrosis · Phase 2 · terminated
NCT03745196 — The Effect of PC945 on Aspergillus or Candida Lung Infections in Patients With Asthma or Chronic Respiratory Diseases · Phase 2 · terminated

Other recruiting trials for Aspergillosis

Currently open trials in the same condition.

NCT05045391 — Pulmonary Aspergillosis in Tuberculosis Patients · active not recruiting
NCT03828773 — PTX3-targeted Antifungal Prophylaxis · NA · recruiting

Other Pulmocide Ltd trials

Trials by the same sponsor.

NCT05238116 — Safety and Efficacy of PC945 (Opelconazole) in Combination With Other Antifungal Therapy for the Treatment of Refractory · Phase 3 · terminated
NCT05037851 — A Safety Study of PC945 (Opelconazole) Prophylaxis or Pre-emptive Therapy Against Pulmonary Aspergillosis in Lung Transp · Phase 2 · completed
NCT03870841 — The Effect of PC945 on Aspergillus Fumigatus Lung Infection in Patients With Cystic Fibrosis · Phase 2 · terminated
NCT03745196 — The Effect of PC945 on Aspergillus or Candida Lung Infections in Patients With Asthma or Chronic Respiratory Diseases · Phase 2 · terminated
NCT03715023 — Anti-viral Effect of PC786 on RSV Infection on HSCT Recipients · Phase 2 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03905447 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Pulmocide Ltd
Last refreshed: 16 July 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03905447.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing